Published in Int J Cancer on September 09, 1992
Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut (2011) 1.91
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest (2015) 1.68
MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology (2012) 1.48
Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol (2005) 1.32
Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg (1998) 1.32
Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res (2005) 1.23
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res (2008) 1.18
Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut (2011) 1.08
H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res (2009) 1.06
Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis. Int J Cancer (2009) 1.04
Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient. World J Gastroenterol (2006) 0.96
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol (2011) 0.94
Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. Int J Cancer (2010) 0.91
Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest (2010) 0.88
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World J Gastroenterol (2007) 0.87
Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines. Clin Exp Immunol (1999) 0.87
Retracted 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins. J Biol Chem (2013) 0.84
NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia. Am J Pathol (1997) 0.83
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol (2010) 0.83
Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest (2012) 0.82
miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth. J Hepatol (2016) 0.81
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. Tumour Biol (2015) 0.81
The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget (2015) 0.81
Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma. Clin Exp Metastasis (2007) 0.81
Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. Am J Physiol Cell Physiol (2011) 0.81
The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complement Altern Med (2015) 0.80
Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA. World J Gastroenterol (2011) 0.80
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer. PLoS One (2016) 0.79
BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Sci (2015) 0.78
Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. Cancer Res (2015) 0.77
Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo. Gastroenterol Res Pract (2013) 0.76
Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget (2017) 0.76
Notch3 drives development and progression of cholangiocarcinoma. Proc Natl Acad Sci U S A (2016) 0.75
Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol (2017) 0.75
Do PPARgamma Ligands Suppress the Growth of Cholangiocarcinoma or the Cholangiohepatitis Induced by the Tumor? PPAR Res (2008) 0.75
miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. Am J Pathol (2017) 0.75
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Lett (2016) 0.75
Evolution of liver transplantation. Hepatology (1982) 19.54
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 5.91
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med (1981) 5.76
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Natural cell-mediated immunity. Adv Cancer Res (1978) 5.53
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Natural killer cells: their roles in defenses against disease. Science (1981) 4.59
Liver transplantation (1). N Engl J Med (1989) 4.53
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer (1975) 3.54
Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol (1977) 3.52
Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol (1984) 3.07
Fungal infections in liver transplant recipients. Transplantation (1985) 3.07
Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol (1981) 3.05
Experience with 150 liver resections. Ann Surg (1983) 3.01
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Liver transplantation (2). N Engl J Med (1989) 2.93
Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet (1981) 2.92
Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Liver transplantation in adults. Hepatology (1982) 2.89
Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet (1985) 2.88
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80
Major hepatic resection for neoplasia: personal experience in 108 patients. Ann Surg (1978) 2.80
Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol (1979) 2.80
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1977) 2.60
Portal vein grafts in hepatic transplantation. Surg Gynecol Obstet (1985) 2.59
Heterogeneity of natural killer cells. Annu Rev Immunol (1984) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Liver transplantation, 1980, with particular reference to cyclosporin-A. Transplant Proc (1981) 2.49
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids. Surg Gynecol Obstet (1982) 2.42
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer (1977) 2.39
Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med (1989) 2.33
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res (2007) 2.24
Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol (1988) 2.21
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20
Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
Left hepatic trisegmentectomy. Surg Gynecol Obstet (1982) 2.16
Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation. Semin Liver Dis (1985) 2.16
A growth factor in fine vascular anastomoses. Surg Gynecol Obstet (1984) 2.15